EML4-ALK AND ITS INHIBITORS: A NEW PARADIGM IN CANCER TREATMENT

被引：0
|
作者：
Mano, H. [1 ,2 ]
机构：
[1] Jichi Med Univ, Div Funct Genom, Shimotsuke, Japan
[2] Univ Tokyo, Grad Sch Med, Dept Med Genom, Tokyo 1138654, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：79 / 79
页数：1
相关论文
共 50 条
  • [21] EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
    Koivunen, Jussi P.
    Mermel, Craig
    Zejnullahu, Kreshnik
    Murphy, Carly
    Lifshits, Eugene
    Holmes, Alison J.
    Choi, Hwan Geun
    Kim, Jhingook
    Chiang, Derek
    Thomas, Roman
    Lee, Jinseon
    Richards, William G.
    Sugarbaker, David J.
    Ducko, Christopher
    Lindeman, Neal
    Marcoux, J. Paul
    Engelman, Jeffrey A.
    Gray, Nathanael S.
    Lee, Charles
    Meyerson, Matthew
    Janne, Pasi A.
    CLINICAL CANCER RESEARCH, 2008, 14 (13) : 4275 - 4283
  • [22] EML4-ALK Translocation in Lung Cancer: An Institutional Clinical Experience
    Bertino, E. M.
    Zhao, W.
    Villalona-Calero, M.
    Otterson, G. A.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S532 - S532
  • [23] EML4-ALK fusion lung cancer:: A rare acquired event
    Perner, Sven
    Wagner, Patrick L.
    Demichelis, Francesca
    Mehra, Rohit
    LaFargue, Chris J.
    Moss, Benjamin J.
    Arbogast, Stefanie
    Soltermann, Alex
    Weder, Walter
    Giordano, Thomas J.
    Beer, David G.
    Rickman, David S.
    Chinnaiyan, Arul M.
    Moch, Holger
    Rubin, Mark A.
    NEOPLASIA, 2008, 10 (03): : 298 - 302
  • [24] Endobronchial Metastases in Lung Cancer Harboring EML4-ALK Rearrangement
    Ijichi, Miharu
    Fukuda, Yosuke
    Kashima, Ayaka
    Sagara, Hironori
    INTERNAL MEDICINE, 2023, 62 (13) : 2021 - 2022
  • [25] Identification of optimal treatment sequence and acquired resistance mechanisms of ALK inhibitors using EML4-ALK transgenic mouse model
    Pyo, Kyoung-Ho
    Min, Lim Sun
    Kim, Jae Hwan
    Lee, Ji Min
    Jo, Ha Ni
    Cho, Jae Soek
    Yun, Mi-Ran
    Kim, Sung Eun
    Kim, Hye Ryun
    Xin, Chun-Feng
    Kim, Tae-Min
    Cho, Byoung Chul
    CANCER RESEARCH, 2018, 78 (13)
  • [26] EML4-ALK: Honing In on a New Target in Non-Small-Cell Lung Cancer
    Horn, Leora
    Pao, William
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) : 4232 - 4235
  • [27] The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement
    Bilgin, Burak
    Sendur, Mehmet Ali Nahit
    Yucel, Sebnem
    Hizal, Mutlu
    Guner, Gurkan
    Akyurek, Nalan
    Erol, Cihan
    Akinci, Muhammed Bulent
    Dede, Didem Sener
    Yalcin, Bulent
    Kilickap, Sadettin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (09) : 2637 - 2643
  • [28] The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement
    Burak Bilgin
    Mehmet Ali Nahit Şendur
    Şebnem Yücel
    Mutlu Hizal
    Gürkan Güner
    Nalan Akyürek
    Cihan Erol
    Muhammed Bülent Akıncı
    Didem Şener Dede
    Bülent Yalçın
    Sadettin Kılıçkap
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 2637 - 2643
  • [29] Route development and scale-up of macrocyclic inhibitors for the EML4-ALK project
    Hoffman, Jacqui
    Sach, Neal
    Richardson, Paul
    Deal, Judy
    Smith, Graham
    Phuong Le
    He, Mingying
    Collins, Michael
    Li, Bryan
    Zhu, Peter
    Zhu, Jinjiang
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [30] EML4-ALK Rearrangement and Its Therapeutic Implications in Inflammatory Myofibroblastic Tumors
    Vargas-Madueno, Fernando
    Gould, Edwin
    Valor, Raul
    Ngo, Nhu
    Zhang, Linsheng
    Villalona-Calero, Miguel A.
    ONCOLOGIST, 2018, 23 (10): : 1127 - 1132
12345